0001104659-23-056766.txt : 20230508 0001104659-23-056766.hdr.sgml : 20230508 20230508060347 ACCESSION NUMBER: 0001104659-23-056766 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230508 DATE AS OF CHANGE: 20230508 EFFECTIVENESS DATE: 20230508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Eucrates Biomedical Acquisition Corp. CENTRAL INDEX KEY: 0001822929 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 001-39650 FILM NUMBER: 23895746 BUSINESS ADDRESS: STREET 1: 250 WEST 55TH STREET, SUITE 13D CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 710-5220 MAIL ADDRESS: STREET 1: 250 WEST 55TH STREET, SUITE 13D CITY: NEW YORK STATE: NY ZIP: 10019 15-12G 1 tm2314860d1_1512g.htm 15-12G

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 15

 

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File No. 001-39650

 

 

 

EUCRATES BIOMEDICAL ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

 

 

 

250 West 55th Street, Suite 13D

New York, New York 10019

(212) 710-5220

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Units, each consisting of one ordinary share, no par value, and one-third of one Warrant

Ordinary shares, no par value

Warrants, each whole warrant exercisable for one ordinary share at an exercise price of $11.50 per share (Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

 

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

  Rule 12g-4(a)(1) x
  Rule 12g-4(a)(2) ¨
  Rule 12h-3(b)(1)(i) x
  Rule 12h-3(b)(1)(ii) ¨
  Rule 15d-6 ¨
  Rule 15d-22(b) ¨

 

Approximate number of holders of record as of the certification or notice date: One.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Eucrates Biomedical Acquisition Corp. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

 

 

 

 

 

  EUCRATES BIOMEDICAL ACQUISITION CORP.
     
Date: May 8, 2023    
  By: /s/ Gonzalo Cordova
  Name: Gonzalo Cordova
  Title: Chief Financial Officer